The FDA moved approved marijuana products to schedule III to expand therapy access and state medical programs while maintaining federal controls.

On April 22, 2026, the Acting U.S. Attorney General ordered two categories of marijuana moved from Schedule I to Schedule III of the Controlled Substances Act (CSA): FDA-approved drug products ...

A major shift in federal marijuana policy could reshape parts of Ohio's cannabis industry, giving medical marijuana businesses tax relief and new legitimacy— while leaving recreational use in a legal ...

The order places FDA-approved products containing marijuana and state-regulated medical marijuana products at a lower drug classification.

If board members object to a federal change, they must publicly issue their reasons and allow for a hearing process before ...

The directive aims to expand access to medical researchers.

The Justice Department reclassified marijuana as a Schedule III drug, a shift that affects research and taxes but not legalization ...

The Justice Department said the drug will now be listed on Schedule III, similar to some common prescription painkillers. The order does not decriminalize marijuana for recreational use.

The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. ...

The move also essentially splits the cannabis market in states that have legalized weed for both medical and recreational consumers.

State Sen. Mike Bohacek announced on Monday his plans to draft 2027 legislation that would legalize medical marijuana in ...

(The Center Square) – Gov. Josh Shapiro thinks the Trump administration took an “important step” on Thursday after it redefined how the federal government classifies medical marijuana. Acting U.S.